These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29558040)

  • 1. Decoy receptor 3 alleviates hepatic fibrosis through suppressing inflammation activated by NF-κB signaling pathway.
    Jin Z; Liu S; Zhan Q; Shao X; Ma J; Pan L
    Adv Clin Exp Med; 2018 Apr; 27(4):441-447. PubMed ID: 29558040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liuweiwuling tablets attenuate BDL-induced hepatic fibrosis via modulation of TGF-β/Smad and NF-κB signaling pathways.
    Liu H; Dong F; Li G; Niu M; Zhang C; Han Y; He L; Yin P; Wang B; Sang X; Li R; Wang J; Bai Z; Xiao X
    J Ethnopharmacol; 2018 Jan; 210():232-241. PubMed ID: 28864168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway.
    Shi H; Dong L; Jiang J; Zhao J; Zhao G; Dang X; Lu X; Jia M
    Toxicology; 2013 Jan; 303():107-14. PubMed ID: 23146752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decoy receptor 3 suppresses TLR2-mediated B cell activation by targeting NF-κB.
    Huang ZM; Kang JK; Chen CY; Tseng TH; Chang CW; Chang YC; Tai SK; Hsieh SL; Leu CM
    J Immunol; 2012 Jun; 188(12):5867-76. PubMed ID: 22581854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pien-Tze-Huang ameliorates hepatic fibrosis via suppressing NF-κB pathway and promoting HSC apoptosis.
    Zheng H; Wang X; Zhang Y; Chen L; Hua L; Xu W
    J Ethnopharmacol; 2019 Nov; 244():111856. PubMed ID: 30959141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis.
    Xiu Z; Shen H; Tian Y; Xia L; Lu J
    Cytokine; 2015 Apr; 72(2):185-9. PubMed ID: 25647275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis.
    Son G; Iimuro Y; Seki E; Hirano T; Kaneda Y; Fujimoto J
    Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G631-9. PubMed ID: 17640975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis.
    Hayashi S; Nishiyama T; Miura Y; Fujishiro T; Kanzaki N; Hashimoto S; Matsumoto T; Kurosaka M; Kuroda R
    Osteoarthritis Cartilage; 2011 Jul; 19(7):903-10. PubMed ID: 21420502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin pretreatment exerts anti-inflammatory effects in hepatic ischemia/reperfusion-injured rats via suppression of the TLR2/NF-κB pathway.
    Liu QS; Cheng ZW; Xiong JG; Cheng S; He XF; Li XC
    Transplant Proc; 2015 Mar; 47(2):283-9. PubMed ID: 25769561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression.
    Yang CR; Hsieh SL; Ho FM; Lin WW
    J Immunol; 2005 Feb; 174(3):1647-56. PubMed ID: 15661928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-driven up-regulation of decoy receptor 3 in keratinocytes contributes to the pathogenesis of psoriasis.
    Wu NL; Huang DY; Hsieh SL; Hsiao CH; Lee TA; Lin WW
    Biochim Biophys Acta; 2013 Oct; 1832(10):1538-48. PubMed ID: 23707413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,25(OH)2D3 downregulates the Toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats.
    Wang H; Zhang Q; Chai Y; Liu Y; Li F; Wang B; Zhu C; Cui J; Qu H; Zhu M
    J Endocrinol Invest; 2015 Oct; 38(10):1083-91. PubMed ID: 25906757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zi Qi Decoction Alleviates Liver Fibrosis by Inhibiting the Toll-Like Receptor 4 (TLR4)-Related Nuclear Factor kappa b (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) Signaling Pathways.
    Zhou J; Zhang X; Wan L; Yu J; Li T; Lu Z; Fang N; Sun L; Ye F
    Med Sci Monit; 2021 Apr; 27():e929438. PubMed ID: 33850093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
    Cheng CP; Sheu MJ; Sytwu HK; Chang DM
    Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-fibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats.
    Chong LW; Hsu YC; Chiu YT; Yang KC; Huang YT
    J Biomed Sci; 2006 May; 13(3):403-18. PubMed ID: 16604421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterisation of decoy receptor 3 in Crohn's disease.
    Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
    Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor-kappaB decoy oligodeoxynucleotides attenuates ischemia/reperfusion injury in rat liver graft.
    Xu MQ; Shuai XR; Yan ML; Zhang MM; Yan LN
    World J Gastroenterol; 2005 Nov; 11(44):6960-7. PubMed ID: 16437600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunomodulator decoy receptor 3 improves locomotor functional recovery after spinal cord injury.
    Chiu CW; Huang WH; Lin SJ; Tsai MJ; Ma H; Hsieh SL; Cheng H
    J Neuroinflammation; 2016 Jun; 13(1):154. PubMed ID: 27316538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
    Yang CR; Wang JH; Hsieh SL; Wang SM; Hsu TL; Lin WW
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S97-107. PubMed ID: 15002040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DXXK exerts anti-inflammatory effects by inhibiting the lipopolysaccharide-induced NF-κB/COX-2 signalling pathway and the expression of inflammatory mediators.
    Yu Y; Li X; Qu L; Chen Y; Dai Y; Wang M; Zou W
    J Ethnopharmacol; 2016 Feb; 178():199-208. PubMed ID: 26571085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.